B-cell-Targeted therapies in relapsing forms of MS

Divyanshu Dubey, Thomas Forsthuber, Eoin P. Flanagan, Sean J. Pittock, Olaf Stüve

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

In recent years, there has been a significant increase in the therapeutic options available for the management of relapsing forms of MS. Therapies primarily targeting B cells, including therapeutic anti-CD20 monoclonal antibodies, have been evaluated in phase I, phase II, and phase III clinical trials. Results of these trials have shown their efficacy and relatively tolerable adverse effect profiles, suggesting a favorable benefit-To-risk ratio. In this review, we discuss the pathogenic role of B cells in MS and the rationale behind the utilization of B-cell depletion as a therapeutic cellular option. We also discuss the data of clinical trials for anti-CD20 antibodies in relapsing forms of MS and existing evidence for other B-cell-directed therapeutic strategies.

Original languageEnglish (US)
Article numbere405
JournalNeurology: Neuroimmunology and NeuroInflammation
Volume4
Issue number6
DOIs
StatePublished - Oct 23 2017

Fingerprint

Cell- and Tissue-Based Therapy
B-Lymphocytes
Therapeutics
Phase III Clinical Trials
Anti-Idiotypic Antibodies
Odds Ratio
Monoclonal Antibodies
Clinical Trials

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

B-cell-Targeted therapies in relapsing forms of MS. / Dubey, Divyanshu; Forsthuber, Thomas; Flanagan, Eoin P.; Pittock, Sean J.; Stüve, Olaf.

In: Neurology: Neuroimmunology and NeuroInflammation, Vol. 4, No. 6, e405, 23.10.2017.

Research output: Contribution to journalReview article

Dubey, Divyanshu ; Forsthuber, Thomas ; Flanagan, Eoin P. ; Pittock, Sean J. ; Stüve, Olaf. / B-cell-Targeted therapies in relapsing forms of MS. In: Neurology: Neuroimmunology and NeuroInflammation. 2017 ; Vol. 4, No. 6.
@article{cca82d82eb4744e9b8c16cdbe63c6fe3,
title = "B-cell-Targeted therapies in relapsing forms of MS",
abstract = "In recent years, there has been a significant increase in the therapeutic options available for the management of relapsing forms of MS. Therapies primarily targeting B cells, including therapeutic anti-CD20 monoclonal antibodies, have been evaluated in phase I, phase II, and phase III clinical trials. Results of these trials have shown their efficacy and relatively tolerable adverse effect profiles, suggesting a favorable benefit-To-risk ratio. In this review, we discuss the pathogenic role of B cells in MS and the rationale behind the utilization of B-cell depletion as a therapeutic cellular option. We also discuss the data of clinical trials for anti-CD20 antibodies in relapsing forms of MS and existing evidence for other B-cell-directed therapeutic strategies.",
author = "Divyanshu Dubey and Thomas Forsthuber and Flanagan, {Eoin P.} and Pittock, {Sean J.} and Olaf St{\"u}ve",
year = "2017",
month = "10",
day = "23",
doi = "10.1212/NXI.0000000000000405",
language = "English (US)",
volume = "4",
journal = "Neurology: Neuroimmunology and NeuroInflammation",
issn = "2332-7812",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - B-cell-Targeted therapies in relapsing forms of MS

AU - Dubey, Divyanshu

AU - Forsthuber, Thomas

AU - Flanagan, Eoin P.

AU - Pittock, Sean J.

AU - Stüve, Olaf

PY - 2017/10/23

Y1 - 2017/10/23

N2 - In recent years, there has been a significant increase in the therapeutic options available for the management of relapsing forms of MS. Therapies primarily targeting B cells, including therapeutic anti-CD20 monoclonal antibodies, have been evaluated in phase I, phase II, and phase III clinical trials. Results of these trials have shown their efficacy and relatively tolerable adverse effect profiles, suggesting a favorable benefit-To-risk ratio. In this review, we discuss the pathogenic role of B cells in MS and the rationale behind the utilization of B-cell depletion as a therapeutic cellular option. We also discuss the data of clinical trials for anti-CD20 antibodies in relapsing forms of MS and existing evidence for other B-cell-directed therapeutic strategies.

AB - In recent years, there has been a significant increase in the therapeutic options available for the management of relapsing forms of MS. Therapies primarily targeting B cells, including therapeutic anti-CD20 monoclonal antibodies, have been evaluated in phase I, phase II, and phase III clinical trials. Results of these trials have shown their efficacy and relatively tolerable adverse effect profiles, suggesting a favorable benefit-To-risk ratio. In this review, we discuss the pathogenic role of B cells in MS and the rationale behind the utilization of B-cell depletion as a therapeutic cellular option. We also discuss the data of clinical trials for anti-CD20 antibodies in relapsing forms of MS and existing evidence for other B-cell-directed therapeutic strategies.

UR - http://www.scopus.com/inward/record.url?scp=85034059469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034059469&partnerID=8YFLogxK

U2 - 10.1212/NXI.0000000000000405

DO - 10.1212/NXI.0000000000000405

M3 - Review article

C2 - 29082296

AN - SCOPUS:85034059469

VL - 4

JO - Neurology: Neuroimmunology and NeuroInflammation

JF - Neurology: Neuroimmunology and NeuroInflammation

SN - 2332-7812

IS - 6

M1 - e405

ER -